Premium
Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study
Author(s) -
Yoshimura Reiji,
Kakihara Shingo,
UmeneNakano Wakako,
Sugita Atsuko,
Hori Hikaru,
Ueda Nobuhisa,
Nakamura Jun
Publication year - 2008
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.928
Subject(s) - caffeine , risperidone , cotinine , nicotine , antipsychotic , medicine , schizophrenia (object oriented programming) , clozapine , pharmacology , cigarette smoking , drug , anesthesia , psychiatry
Excessive cigarette smoking and caffeine intake are often seen in schizophrenic patients being treated with antipsychotic drugs, particularly typical antipsychotic drugs. Using nicotine and caffeine sometimes influences psychotic symptoms in these patients. Clozapine is the only antipsychotic drug reported to reduce the amount of cigarette smoking, however, still remains controversial of its efficacy. In the present study, we examined the effect of acute risperidone treatment on the amount of cigarette smoking and plasma levels of cotinine and caffeine in schizophrenic patients. Treatment with risperidone for 4 weeks did not increase daily cigarette consumption or plasma levels of cotinine and caffeine. The results suggest that acute risperidone treatment does not promote the intake of nicotine and caffeine at least by 4 weeks in schizophrenic patients. Copyright © 2008 John Wiley & Sons, Ltd.